Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme.
Authors
Khan, FOttensmeier, C
Popat, S
Dua, D
Dorey, N
Ellis, S
Szabo, M
Upadhyay, S
Califano, Raffaele
Chan, S
Lee, L
Ali, C
Nicolson, M
Bates, A
Button, M
Chaudhuri, A
Mulvenna, P
Shaw, H
Danson, S
Affiliation
Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield S10 2SJ, United Kingdom.Issue Date
2014-04-09
Metadata
Show full item recordAbstract
Afatinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) who were previously sensitive to erlotinib or gefitinib. This study investigated experience of afatinib under a Named Patient Use (NPU) programme.Citation
Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. 2014: Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2014.03.001PubMed ID
24726055Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2014.03.001
Scopus Count
Collections
Related articles
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.
- Authors: Kim Y, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM
- Issue date: 2019 Apr
- Clinical analysis of EGFR-positive non-small cell lung cancer patients treated with first-line afatinib: A Nagano Lung Cancer Research Group.
- Authors: Sonehara K, Kobayashi T, Tateishi K, Morozumi N, Yoshiike F, Hachiya T, Ono Y, Takasuna K, Agatsuma T, Masubuchi T, Matsuo A, Tanaka H, Morikawa A, Hanaoka M, Koizumi T
- Issue date: 2019 May
- First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
- Authors: Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K
- Issue date: 2019 Jun
- Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
- Authors: Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F
- Issue date: 2014 Nov
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
- Authors: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL
- Issue date: 2014 Feb